Piramal Pharma Solutions Deploys 4.3 MWp Solar Plant at UK Drug Substance/Product Facility
- Piramal Pharma Solutions is installing a 4.3 MWp ground-mounted solar plant at its integrated Morpeth, UK facility, expected to generate 3,950 MWh annually.
- The solar installation will cover approximately 22% of the site's electricity demand and avoid an estimated 20,000 tCO₂e emissions over 25 years, with operations beginning Q1 2027.
Operational Impact
Piramal's Morpeth facility will reduce grid electricity dependency by 22% through onsite solar generation, lowering operational costs and enhancing energy supply stability for integrated drug substance and product manufacturing.
Source: PharmaSource RSS
ProBio and Kun Tuo (IQVIA) Launch Integrated CDMO-CRO Partnership for China Biologics Development
- ProBio (CDMO) and Kun Tuo (IQVIA's China CRO) formed a strategic partnership to provide end-to-end support for biologics and cell/gene therapy development in China, covering CMC, non-clinical studies, and clinical operations.
- ProBio has manufactured over 1,000 GMP batches and supported 90+ IND/IIT programs; Kun Tuo has managed 1,400+ clinical trials and employs ~1,000 staff across China's clinical research network.
- The integrated model aims to streamline development pathways for global sponsors by coordinating manufacturing, regulatory, and clinical trial execution through a single partnership.
Operational Impact
ProBio's China CDMO-CRO integration with Kun Tuo expands integrated development capacity for CGT sponsors entering China, reducing coordination friction between manufacturing scale-up and clinical site engagement.
Source: PharmaSource RSS